The apoptosis-inducing ability of α-ethano bridged crinane alkaloids was investigated using natural and semi-synthetic derivatives uncovering novel structural requirements of this cytotoxic pharmacophore. An α-ethano bridge is required; an αor ß-methoxy or hydroxyl H-bond acceptor are all tolerated at C-3; a small substituent (H, or OH) alone is tolerated at C-11; and a C-1 to C-2 double bond is shown to modulate, but is not a requirement for, apoptosis-inducing activity.
Alkaloids of the Amaryllidaceae plant family continue to attract significant attention in view of their fascinating structural features and varied biological activities [1, 2] .
Research in our laboratories has focused on the discovery and development of both natural [3, 4] and synthetic [5] cytotoxic alkaloids and derivatives of the Amaryllidaceae (Scheme 1) for several years. Three classic structural types [2] are recognized as the lycorane-type, including pancratistatin 2, galanthamine-type including galanthamine 3 and the crinane-type, exemplified by crinamine 4. All of these derive biosynthetically from the common amino acid-derived precursor norbelladine 1 [1] . Several other more complex structural types are also now well known to occur within the Amaryllidaceae [2] [3] [4] . Our synthetic efforts [5] in this area have focused largely on the lycorane-type alkaloid pancratistatin 2 from a SAR-based approach, inspired by its potent and selective anticancer properties [6] . While the alkaloid's mechanism of action remains elusive, it has been shown that pancratistatin induces apoptosis selectively in cancer cells, with minimal effect on normal cells, and that the mitochondria are the site of action [7] . Evidence was obtained that the apoptotic mode of cell death in cancer cells was related to early activation of caspase-3 followed by flipping of phosphatidyl serine [8] . In the galanthamine series, efforts by several workers on the acetylcholinesterase inhibitor galanthamine 3 have led to its scheduling in the treatment of Alzheimer's and other neuro-degenerative diseases [9] . Significantly, galanthamine hydrobromide, under the generic name Reminyl, is the first of the Amaryllidaceae alkaloids to be approved as a pharmaceutical in the treatment of a human disease. Thus, while the lycorane-and galanthamine-type alkaloids have attracted much interest due to their pharmaceutical appeal as biologically-privileged molecules, less attention has been directed towards bases of the crinane structural type. These alkaloids have been shown to exhibit a range of biological activities [10] . The cytotoxicity of crinamine 4 to the malarial parasite and to a series of tumor cell lines was reported [11] , while the activity of 6hydroxycrinamine against mouse melanoma cells has been documented [12] , and haemanthamine 6 is known to inhibit protein synthesis and have antiproliferative action [13, 14] . Motivated by these interesting observations, our research groups previously examined a mini-library of crinane alkaloids for apoptosis-inducing activity [15] . In particular, we reported that the α-5,10b-ethano bridge, present in crinamine 4 and haemanthamine 6, was a crucial requirement for the selective induction of apoptosis in rat hepatoma cancer cells. Significantly, no effect was observed on similar treatment to normal HEK 293t cells [15] . This potent and cancer cell-line selective activity prompted us to continue a study on related natural and synthetic derivatives in order to further refine this interesting pharmacophore. To summarise previous findings, structural requirements for apoptosis activity were found to include: i) a free hydroxyl group at C-11, ii) the presence of the α-5,10b-ethano bridge, and iii) that either an αor ß-methoxy substituent at C-3 was tolerated [15] .
Based on these findings, this structure-based probe of the pharmacophoric elements required for the induction of apoptosis is now extended to four new α-ethano bridged crinane compounds that have provided further insights into the requirements. The α-ethano bridged alkaloids hamayne 5 and vittatine 7 were re-isolated as previously described [12, 16] . In addition, two new dihydro-α-ethano bridged crinane derivatives, dihydrocrinamine 8 and dihydrohamayne 9, were prepared by hydrogenation of crinamine 4 and hamayne 5, respectively. It was of interest to prepare the dihydro analogues in order to probe the possibility that the alkenes might function as pro-drugs. Peroxidase or haloperoxidase-type transformation of the olefins would deliver a polyhydroxylated core not unlike that found in the potent apoptosis-inducing pancratistatin series. Hydrogenation of 4 and 5 was conducted using a palladium on charcoal catalyst delivering the desired dihydro analogues 8 and 9 in good yield. Diagnostically, the 1 H and 13 C NMR spectra of 8 and 9 (see Experimental) indicated loss of olefination and appearance of new upfield-shifted aliphatic peaks attributable to 2H-1/C-1 and 2H-2/C-2.
This new mini-library consisting of compounds 5, 7, 8 and 9 was screened for apoptosis inducing activity using human leukemia cells (Jurkat). Vittatine 7 was identified as exhibiting significantly enhanced apoptosis-inducing activity after 24 hrs incubation, similar in potency to crinamine 4 and haemanthamine 6 [1]. Cells affected by the treatment exhibited characteristic apoptotic morphology with condensed nuclei brightly stained with Hoechst dye as shown in Figure 1A . Apoptotic cell death was further confirmed by monitoring the flipping of phosphatidyl serine to the outer leaflet of the membrane by the Annexin-V binding assay as shown in Figure 1B .
A dose response study revealed the potency of 7, Figure 2A . Approximately 65% of Jurkat cells were shown to be apoptotic after a single 20 μM treatment after 24 hrs. Under similar conditions, crinamine 4 and haemanthamine 6 were observed to effectively induce apoptosis at 25 μM after 24 hrs in Jurkat cells with 85% to >90% of all cells displaying characteristic apoptotic morphology [15] . Furthermore, 10 μM vittatine 7 treatment induced caspase-3 activation at 18 hrs indicating caspase-3dependent apoptosis, as shown in Figure 2B . Thus vittatine 7 is now identified as a potent inducer of apoptosis in the crinane series, as indicated by nuclear condensation, phosphatidyl serine flipping, and caspase-3 activation assays. It is also worthwhile noting that the natural product crinine, which is in fact ent-vittatine 7, hence incorporating a ß-ethano bridge was previously tested for activity [15] . Crinine was found to be devoid of any apotosis-inducing activity. This result confirms the absolute stereochemical requirement incorporating the α-bridge that is required for anticancer activity.
Three further aspects of this interesting pharmacophore are worthy of comment. First of all, the overall results confirm the potency of the C-3 ß-methoxy derivative 6 [15] and of the ß-hydroxy derivative 7, irrespective of the presence of a hydroxyl group or methylene at position C-11. Furthermore, while the α-methoxy derivative 4 is potent alone [15] , activity drops in the case of the C-3 α-hydroxy derivative 5. While either configuration of the C-3 methoxy group is tolerated, a C-3 α-hydroxyl 5 negatively affects the apoptosis inducing potency in contrast to the very active C-3 ß-hydroxyl containing derivative 7. It is also noted that a C-3 ß-hydroxyl group is a known pharmacophoric element for potent apoptosis induction in the pancratistatin series (see Scheme 1) [5c].
Secondly, previous results indicated that the C-11 hydroxyl group was a necessary pharmacophoric element as acylation (acetylation and benzoylation) resulted in a loss of apoptosis inducing activity [15] . The significant activity displayed by vitattine 7, having a C-11 methylene, now strongly indicates that either a hydroxyl or hydrogen substituent is tolerated at C-11, but that an acetoxy or benzoyloxy substituent is not. This appears to be attributable to steric factors alone, as opposed to the H-bond donor/acceptor ability at this site. It appears that the substituent at C-11 must occupy a fairly small pocket in the active site that does not involve hydrogen bonding.
Finally, reduction of the C-1 to C-2 double bond resulted in a significant decrease in activity in the case of compound 8 (from 4), but slightly increased activity in the case of the C-3 α-hydroxyl derivative 9 (from 5). The most significant effect is seen with crinamine 4, which was previously shown to be the most potent inducer of apoptosis in this series [15] . Hydrogenation of 4 yields the dihydrocrinamine analogue 8, now one of the least active members of this series. On the other hand, the mild apoptosis inducing activity of hamayne 5 was enhanced in conversion to its dihydro derivative 9. It was also of interest to prepare the dihydro-derivatives 8 and 9 in consideration of the possibility that the olefin in 4 and 5 might function as a pro-pharmacophoric element, being transformed in vivo to an active drug, for example an epoxide or diol. The introduction of 1,2-diol functionality to crinanes such as 4 is strongly reminiscent of the more oxidized ring-C active compounds, such as pancratistatin. While such an effect could be argued for the potency of crinamine 4 in comparison to its dihydro derivative 8, the results with dihydrohamayne 9 and vittatine 7 caution against drawing a direct analogy to the lycorane series. The present results with C-3 hydroxyl compounds 7 and 9, as well as our previous findings with C-3 methoxy derivatives crinamine 4 and haemanthamine 6 [15] , now indicate that a single H-bond acceptor (hydroxyl or methoxy group) alone is sufficient, irrespective of configuration at C3. The lower activities of 5 and 8 are most likely due to small conformational effects in the positioning of the C-3 H-bond acceptor. Nonetheless, the results now clearly show that a Δ 1,2 double bond is not a critical pharmocophoric requirement.
The present study further advances our understanding of the pharmacophoric requirements in the crinane series of apoptosis-inducing alkaloids. The structural features are now known to include the following. i) An α-oriented 5,10b-ethano bridge is required. Interestingly, this renders the B/C-ring junction conformationally similar to that found in pancratistatin and related apoptosis-inducing alkaloids. ii) The presence of a C-1 to C-2 double bond is not a strict requirement, since hydrogenation produced more or less active derivatives depending upon the C-3 substituent. The double bond is now shown to modulate activity slightly, results that may be attributed to conformational effects alone. The olefin does not appear to function as a pro-drug element, and hydroxyl functionality is not required at C-1 and C-2, in contrast to the pancratistatin series. iii) Potent derivatives contain either an α-or βconfigured C-3 methoxy group or a C-3 ß-hydroxyl, whereas a C-3 α-hydroxyl group results in slight loss of activity. The results indicate that an H-bond acceptor is required at C-3 and that its positioning is flexible to some degree. iv) The presence of a small substituent alone at C-11 (H or OH), the function of which does not appear to involve hydrogen bonding but is subject to steric constraints alone.
In conclusion, the ability of crinamine 4, haemanthamine 6 and vitattine 7 to induce apoptosis in cancer cells, but not in normal cells, has been demonstrated allowing further refinement of significant structural features of the pharmacophore. In some aspects, the SAR is reminiscent of the potent apoptosis-inducing compound pancratistatin. While some overlap of the cytotoxic pharmacophores is evident, structural differences and other requirements found in the pancratistatin series not found in the apoptosis-inducing crinane alkaloids have now been clearly demonstrated. Given these observations, the crinane and lycorane apoptosis-inducing pharmacophores are best viewed as being distinct, although it may still be possible for these agents to act on the same receptor in a slightly different fashion. Work is ongoing to further refine the pharmacophores in both series and to identify the biological targets operative.
Experimental
Melting points (uncorrected) were measured on a Gallenkamp melting point apparatus. Optical rotations were determined on a Perkin-Elmer 241 polarimeter. IR spectra were measured on a Bio-Rad FTS-40 series spectrometer in dry film. CIMS were run on a Micromass Quattro Ultima spectrometer fitted with a direct injection probe (DIP) with ionization energy set at 70 eV and HRMS (CI) were performed with a Micromass Q-Tof Ultima spectrometer. 1 H and 13 C NMR spectra were recorded on a Bruker AV700 spectrometer in CDCl 3 or CD 3 OD with TMS as internal standard, chemical shifts δ are reported in units of (ppm) and coupling constants (J) are expressed in Hz. Silica gel (Merck 70-230 mesh) was used for CC, silica gel SIL G/UV 254 for analyt. and SIL G-25/UV 254 for prep. TLC (both Macherey-Nagel). Spots on chromatograms were detected under UV light (254 nm) and by Dragendorff's reagent stain.
Extraction and isolation of alkaloids: Crinamine 4, hamayne 5, haemanthamine 6 and vitattine 7 were obtained from authenticated plant sources as previously described [12, 16] and voucher specimens have been deposited in the Herbarium at the National Museum, Bloemfontein, South Africa. All alkaloids were single components by both NMR and thin layer chromatographic analysis.
Cell Culture: Human leukemia (Jurkat) cancer cells employed in this study were purchased from ATCC, Manassas, VA. Cells were grown and maintained in an incubator set at 37°C, 5% CO 2 , and 95% humidity. RPMI-1640 media (Sigma-Aldrich, Oakville, ON) supplemented with 10% fetal bovine serum (FBS) and 10 µg/mL Gentamycin (Life Technologies, Mississauga, ON) was used for cell culture.
Cell treatment:
To explore induction of apoptosis by treatment with the various Amaryllidaceae alkaloids, Jurkat cells were grown and treated for 24, 48, and 72 hr with each alkaloid. Various concentrations of the alkaloids diluted in culture media, from a 10 mM stock in DMSO, ranging from 1 to 20 µM were used and apoptotic induction by alkaloid treatment was calculated.
Cellular staining: Nuclear morphological changes associated with apoptosis were visualized using 10 µM final concentration of cell permeable Hoechst 33342 dye (Molecular Probes, Eugene, OR). Phosphatidyl serine flipping (a biochemical marker of apoptosis) was visualized using Annexin-V-FITC binding assay as per manufacturer's protocol (Molecular Probes, Eugene, OR). Cells were examined using a fluorescent microscope (Leica DM IRB, Germany); pictures were taken at 40X objective. To obtain an apoptotic index, brightly stained condensed nuclei (apoptotic cells) were counted in a minimum of 5 fields, each containing more than 100 cells, so that a minimum of 500 total cells were counted. Data was calculated and an apoptotic index was created such that apoptotic cells were expressed as a percentage of the total number of cells counted. Statistical analysis was performed using STATISTICA from the data of three separate experiments and p < 0.05 was obtained for alkaloid 7.
Caspase-3 Activity Assay:
The caspase-3 assay was carried out using a previously published method [8] . Fluorescence was measured at 400 nm excitation and 505 nm emission using the Spectra Max Gemini XS (Molecular Devices, Sunnyvale, CA). Caspase-3 activity was calculated per microgram of total protein in the extract. Protein concentration was determined utilizing the BioRad protein assay reagent (BioRad, Mississauga, ON, Canada).
Synthesis of Dihydrocrinamine 8:
Crinamine 4 (5.0 mg, 0.0166 mmol) was dissolved at room temperature in dry methanol (0.33 mL) to which was added 10% palladium on carbon (0.0018 mg, 0.00166 mmol) and the reaction vial stoppered with a rubber septum. A balloon of hydrogen was then attached to the vial via a syringe and needle, the solution bled of air and left stirring until TLC (10% MeOH/EtOAc) indicated the reaction to be complete (~6 hrs). The mixture was then filtered through a pad of celite which was washed repeatedly with dry methanol and the crude material obtained after removal of solvent subjected to gel filtration on Sephadex LH-20 eluting with methanol to give dihydrocrinamine 8 as an amorphous gum (4.9 mg, 98%).
[α] 
Synthesis of Dihydrohamayne 9:
Hamayne 5 (5.0 mg, 0.0174 mmol) was dissolved at room temperature in dry methanol (0.34 mL) to which was added 10% palladium on carbon (0.0019 mg, 0.00174 mmol) and the reaction vial stoppered with a rubber septum. A balloon of hydrogen was then attached to the vial via a syringe and needle, the solution bled of air and left stirring until TLC (10% MeOH/EtOAc) indicated the reaction to be complete (~6 hrs). The mixture was then filtered through a pad of celite which was washed repeatedly with dry methanol and the crude material obtained after removal of solvent subjected to gel filtration on Sephadex LH-20 eluting with methanol to give dihydrohamayne 9 as an amorphous gum (4.8 mg, 96%).
